BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Artemis 2 astronauts head for the moon after make-or-break engine burn (video)- Setbacks in Texas and elsewhere put Republicans' redistricting hopes in doubt as key deadlines loom
- April full moon 2026 dazzles as 'Pink Moon' lights up skies worldwide (photos)
- Bomb blast in packed Nigerian mosque kills five
- Germany's Pistorius: NATO protects Europe from Iranian missiles
- Newly discovered link between traumatic brain injury in children and epigenetic changes could help personalize treatment for recovering kids
- Cyber Monday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- Bismuth’s haredi draft bill won’t change enlistment, IDI expert tells 'Post'
- Washington state experiences historic flooding as Skagit River hits record high level. See flooding maps, highway closures and forecasts.
